{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:35:59Z","timestamp":1793140559129,"version":"4.5.0"},"publisher-location":"Chichester, UK","reference-count":41,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd005225.pub2","type":"reference-entry","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T11:55:49Z","timestamp":1276602949000},"source":"Crossref","is-referenced-by-count":17,"title":["Creatine for amyotrophic lateral sclerosis\/motor neuron disease"],"prefix":"10.1002","author":[{"given":"Daniel M.","family":"Pastula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan H","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S","family":"Bedlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD005225.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.10554","article-title":"A randomized sequential trial of creatine in amyotrophic lateral sclerosis","volume":"53","author":"Groeneveld","year":"2003","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD005225.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/17482960802028890","article-title":"Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS","volume":"9","author":"Rosenfeld","year":"2008","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"9","key":"10.1002\/14651858.CD005225.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1212\/01.WNL.0000142992.81995.F0","article-title":"A clinical trial of creatine in ALS","volume":"63","author":"Shefner","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD005225.pub2-BIB4|cit4","series-title":"American Academy of Neurology Annual Meeting","article-title":"Creatine monohydrate in amyotrophic lateral sclerosis: preliminary results","author":"Rosenfeld","year":"2001"},{"issue":"4","key":"10.1002\/14651858.CD005225.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12017-008-8053-y","article-title":"Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases","volume":"10","author":"Adhihetty","year":"2008","journal-title":"Neuromolecular Medicine"},{"issue":"9","key":"10.1002\/14651858.CD005225.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005225.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev.bi.54.070185.004151","article-title":"The creatine-creatine phosphate energy shuttle","volume":"54","author":"Bessman","year":"1985","journal-title":"Annual Review of Biochemistry"},{"issue":"5","key":"10.1002\/14651858.CD005225.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"1-2","key":"10.1002\/14651858.CD005225.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"Journal of the Neurological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD005225.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF00839964","article-title":"The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register","volume":"240","author":"Chancellor","year":"1993","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD005225.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"Journal of the Royal Statistical Society. Series B (Methodological)"},{"issue":"11","key":"10.1002\/14651858.CD005225.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00415-006-0226-8","article-title":"Amyotrophic lateral sclerosis: early predictors of prolonged survival","volume":"253","author":"Czaplinski","year":"2006","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD005225.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1212\/01.WNL.0000049472.47709.3B","article-title":"Prognosis in amyotrophic lateral sclerosis: a population-based study","volume":"60","author":"Aguila","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005225.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/146608202317576534","article-title":"No effect of creatine on respiratory distress in amyotrophic lateral sclerosis","volume":"3","author":"Drory","year":"2002","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"11","key":"10.1002\/14651858.CD005225.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399406010854","article-title":"Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment","volume":"8","author":"Goodall","year":"2006","journal-title":"Expert Reviews in Molecular Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005225.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/17434470410019906","article-title":"ALSFRS-R","volume":"5","author":"Gordon","year":"2004","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"key":"10.1002\/14651858.CD005225.pub2-BIB17|cit17","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"1","key":"10.1002\/14651858.CD005225.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0022-510X(99)00045-3","article-title":"Bipap improves survival and rate of pulmonary function decline in patients with ALS","volume":"164","author":"Kleopa","year":"1999","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD005225.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/6568","article-title":"Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis","volume":"5","author":"Klivenyi","year":"1999","journal-title":"Nature Medicine"},{"issue":"6 (Suppl 4)","key":"10.1002\/14651858.CD005225.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1212\/WNL.47.6_Suppl_4.242S","article-title":"A confirmatory dose-ranging study of riluzole in ALS. ALS\/Riluzole Study Group II","volume":"47","author":"Lacomblez","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005225.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/bbrc.2001.6164","article-title":"Direct antioxidant properties of creatine","volume":"290","author":"Lawler","year":"2002","journal-title":"Biochemical & Biophysical Research Communications"},{"issue":"6","key":"10.1002\/14651858.CD005225.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jnnp.51.6.778","article-title":"Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease","volume":"51","author":"Li","year":"1988","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD005225.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1212\/01.WNL.0000048208.54755.78","article-title":"The epidemiology of ALS in Modena, Italy","volume":"60","author":"Mandrioli","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD005225.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5107(94)70211-X","article-title":"Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function","volume":"40","author":"Mathus-Vliegen","year":"1994","journal-title":"Gastrointestinal Endoscopy"},{"issue":"10","key":"10.1002\/14651858.CD005225.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/BF00866922","article-title":"Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis","volume":"242","author":"Mazzini","year":"1995","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD005225.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-510X(01)00611-6","article-title":"Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results","volume":"191","author":"Mazzini","year":"2001","journal-title":"Journal of the Neurological Sciences"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD005225.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"C365","DOI":"10.1152\/ajpcell.1984.246.5.C365","article-title":"A simple analysis of the \"phosphocreatine shuttle\"","volume":"246","author":"Meyer","year":"1984","journal-title":"American Journal of Physiology"},{"issue":"15","key":"10.1002\/14651858.CD005225.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/WNL.0b013e3181bc0141","article-title":"Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"73","author":"Miller","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD005225.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000086353","article-title":"Survival of patients with amyotrophic lateral sclerosis in a population-based registry","volume":"25","author":"Millul","year":"2005","journal-title":"Neuroepidemiology"},{"issue":"5-6","key":"10.1002\/14651858.CD005225.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/17482960802320545","article-title":"Factors associated with survival in the National Registry of Veterans with ALS","volume":"10","author":"Pastula","year":"2009","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD005225.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11910-003-0041-x","article-title":"Recent advances in amyotrophic lateral sclerosis research","volume":"3","author":"Przedborski","year":"2003","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"6415","key":"10.1002\/14651858.CD005225.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"issue":"22","key":"10.1002\/14651858.CD005225.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","article-title":"Amyotrophic lateral sclerosis","volume":"344","author":"Rowland","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005225.pub2-BIB34|cit34","unstructured":"Sanofi-Aventis Rilutek prescribing information Sanofi-Aventis U.S.LLC, Bridgewater, NJ"},{"issue":"5","key":"10.1002\/14651858.CD005225.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.freeradbiomed.2005.10.035","article-title":"Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity","volume":"40","author":"Sestili","year":"2006","journal-title":"Free Radical Biology and Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005225.pub2-BIB36|cit36","first-page":"338","article-title":"Familial amyotrophic lateral sclerosis","volume":"3","author":"Siddique","journal-title":"Clinical Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD005225.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.59.2.280","article-title":"Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998","volume":"59","author":"Sorenson","year":"2002","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD005225.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/14660820410021311","article-title":"Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period","volume":"5","author":"Testa","year":"2004","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"9","key":"10.1002\/14651858.CD005225.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/jnnp.74.9.1258","article-title":"Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study 1996-2000","volume":"74","author":"Traynor","year":"2003","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD005225.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1212\/01.WNL.0000144345.49510.4E","article-title":"Functional outcome measures as clinical trial endpoints in ALS","volume":"63","author":"Traynor","year":"2004","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD005225.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0022-510X(01)00630-X","article-title":"The epidemiology of motor neuron diseases: a review of recent studies","volume":"191","author":"Worms","year":"2001","journal-title":"Journal of the Neurological Sciences"}],"updated-by":[{"DOI":"10.1002\/14651858.cd005225.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005225.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:46:38Z","timestamp":1628531198000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005225.pub2"}},"subtitle":[],"editor":[{"given":"Daniel M.","family":"Pastula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005225.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD005225.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2010,6,16]]}}}